In November 2017, a Lancet commission on the future of U.S. cancer research priorities released its report (Lancet Oncol. 2017;18:e653–e706; doi:10.1016/S1470-2045(17)30698-8). That report is a call to action—a follow-up to the 10 major aims for progress in U.S. cancer research that a working group of the National Cancer Advisory Board identified. That group consisted of experts in fields such as genomics, biology, and cancer prevention, as well as investigators and cancer advocacy representatives.
http://ift.tt/2AmVhn7
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου